» Articles » PMID: 14613265

Association Between Etanercept Use and Employment Outcomes Among Patients with Rheumatoid Arthritis

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2003 Nov 13
PMID 14613265
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To assess the association between use of etanercept and employment outcomes among patients with rheumatoid arthritis (RA).

Methods: In 1999, 497 RA patients of working ages (18-64 years) reported their employment status in the year of diagnosis and as of the study year, in structured telephone interviews. Of these, 238 had been in clinical trials of etanercept and were currently taking that medication, while 259 were members of an observational study and were not taking etanercept. We used regression techniques to estimate whether employment outcomes in 1999 (employed versus not and, among the employed, hours of work per week, weeks of work per year, and hours of work per year) among the 379 of the 497 patients who were employed at the time of diagnosis were associated with etanercept use, with and without adjustment for demographic characteristics, RA status, overall health status, and the nature of the job held at the time of diagnosis.

Results: At the time of diagnosis, 75% of RA patients from the observational study who did not take etanercept and 77% of those who did take the medication were employed. By 1999, among those employed at diagnosis, 55% of the former group and 71% of the latter were employed (difference 16 percentage points). After adjustment for demographics, overall health status, duration of RA, RA status, and occupation and industry, the difference widened to 20 percentage points. Among all who were employed at the time of diagnosis, those from the etanercept clinical trials worked an average of 5.4 more hours per week in 1999; after adjustment, the etanercept group worked 7.4 more hours per week.

Conclusion: Among all persons who were employed at the time of RA diagnosis, having been in the etanercept clinical trials was associated with higher employment rates in 1999 and a greater number of hours per week of work in that year, suggesting that a randomized trial to establish the relationship between treatment and employment outcomes is now warranted.

Citing Articles

Employment of patients with rheumatoid arthritis - a systematic review and meta-analysis.

Kirkeskov L, Bray K BMC Rheumatol. 2023; 7(1):41.

PMID: 37964371 PMC: 10644429. DOI: 10.1186/s41927-023-00365-4.


Exploring drug cost and disease outcome in rheumatoid arthritis patients treated with biologic and targeted synthetic DMARDs in Norway in 2010-2019 - a country with a national tender system for prescription of costly drugs.

Brkic A, Diamantopoulos A, Haavardsholm E, Fevang B, Brekke L, Loli L BMC Health Serv Res. 2022; 22(1):48.

PMID: 35012522 PMC: 8743354. DOI: 10.1186/s12913-021-07425-w.


Fatigue independently predicts different work disability dimensions in etanercept-treated rheumatoid arthritis and ankylosing spondylitis patients.

Druce K, Aikman L, Dilleen M, Burden A, Szczypa P, Basu N Arthritis Res Ther. 2018; 20(1):96.

PMID: 29843776 PMC: 5972438. DOI: 10.1186/s13075-018-1598-8.


Estimated medical expenditure and risk of job loss among rheumatoid arthritis patients undergoing tofacitinib treatment: post hoc analyses of two randomized clinical trials.

Rendas-Baum R, Kosinski M, Singh A, Mebus C, Wilkinson B, Wallenstein G Rheumatology (Oxford). 2017; 56(8):1386-1394.

PMID: 28460083 PMC: 5850117. DOI: 10.1093/rheumatology/kex087.


The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life.

Fleischmann R Open Access Rheumatol. 2009; 1:95-106.

PMID: 27789984 PMC: 5074715. DOI: 10.2147/oarrr.s4904.